Cluster
Natural Products
Cluster Open
What are natural products?
- Refers to plants, animals, microorganisms, and their metabolites obtained from nature
- Plant-derived natural product resources refer to natural substances that can be extracted, processed, and formulated for use as raw resources, intermediates, or products in pharmaceuticals, functional health foods, and functional cosmetics.
Applications
Why is securing natural product resources and fostering the industry important?
- Between 1981 and 2014, 63% of newly developed drugs were derived from natural products, demonstrating their role as essential raw resources for developing products that promote human health.
- However, with the enforcement of the Nagoya Protocol in October 2014, competition over natural product resources intensified, emphasizing the need for national strategies to secure and utilize these resources.
- The Fourth Industrial Revolution has expanded markets for bio-based resources and convergence technologies, prompting countries worldwide to actively enhance the competitiveness of their natural product industries.
Through the “Natural Products Cluster Promotion Project (2021 –),” domestic infrastructure for natural product resources and R&D is being operated, while the Natural Products Central Bank focuses on securing physical natural resources, distribution, analytical technology, and information support.
Key institutions and research cases on natural product resources
- Provides natural products and extracts in various forms, including individual samples, bulk extracts, raw resources, and powdered samples
- Offers analytical and bioactivity information on natural product resources, and supports research on the isolation and analysis of active compounds
Development of Compositions for the Prevention or Treatment of Cardiovascular Metabolic Diseases (2020)
Korea Research Institute of Bioscience and Biotechnology (KRIBB) developed compositions using extracts, fractions, and isolated compounds from the overseas plant Elaeocarpus petiolatus to inhibit tumor necrosis factor production, thereby suppressing cardiovascular inflammation, and filed a patent.
Development of Compositions for the Prevention or Treatment of Liver Diseases (2022)
The KRIBB developed compositions using extracts of Acanthopanax and Garcinia cambogia and isolated compounds to prevent and treat liver diseases while minimizing side effects, and filed a patent.
Notice
Login is required to use the smarter search experience, BioOneAI Beta.
Proceed to login?
